Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 155, Issue 5, Pages 599-606Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1365-2141.2011.08893.x
Keywords
azacitidine; myelodysplastic syndromes; acute myeloid leukaemia; predictors; platelets
Categories
Ask authors/readers for more resources
The efficacy of azacitidine in the treatment of high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) (20-30% blasts) has been demonstrated. To investigate the efficacy of azacitidine in daily clinical practice and to identify predictors for response, we analysed a cohort of 90 MDS, CMML and AML patients who have been treated in a Dutch compassionate named patient programme. Patients received azacitidine for a median of five cycles (range 1-19). The overall response rate (complete/partial/haematological improvement) was 57% in low risk MDS, 53% in high risk MDS, 50% in CMML, and 39% in AML patients. Median overall survival (OS) was 13.0 (9.8-16.2) months. Multivariate analysis confirmed circulating blasts [Hazard Ratio (HR) 0.48, 95% confidence interval (CI) 0.24-0.99; P = 0.05] and poor risk cytogenetics (HR 0.45, 95% CI 0.22-0.91; P = 0.03) as independent predictors for OS. Interestingly, this analysis also identified platelet doubling after the first cycle of azacitidine as a simple and independent positive predictor for OS (HR 5.4, 95% CI 0.73-39.9; P = 0.10). In conclusion, routine administration of azacitidine to patients with variable risk groups of MDS, CMML and AML is feasible, and subgroups with distinct efficacy of azacitidine treatment can be identified.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available